Upstate Active Clinical Trials
Study Title:A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Upstate Institutional Review Board (IRB) Number:1445012
Patient Age Group:Adults
Principal Investigator:Sam Benjamin, MD
What is involved if I participate?
- How long is the study?
2 years, then maintenance
- Is transportation provided or reimbursed?
- Is parking provided or reimbursed?
Where will the study take place?Upstate Cancer Center
Main University Hospital
Who can I contact for more information?
Name: Alexandra Koulouris, BA